Analysis of participants in the ORACL trial leads researchers to suggest that nonfrail older adults with type 1 diabetes are better off following time in range guidance aimed at younger people.
Lifestyle intervention proves “highly successful” in adults with diabetes aged 65 to 85 years, improving both metabolic and functional health, report researchers.
Deintensifying diabetes treatment does not increase the risk for short-term adverse outcomes in male nursing home residents with limited life expectancy or advanced dementia, say researchers.
A post-hoc analysis of the DAPA-HF trial indicates that dapagliflozin is beneficial in people with heart failure and reduced ejection fraction regardless of frailty, but with the largest gains in the frailest individuals.
Follow-up results from the WISDM trial show that extended use of continuous glucose monitoring leads to reduced hypoglycemia without increasing hyperglycemia risk in older people with type 1 diabetes.
Less than a third of nursing home residents who meet the criteria for overtreatment of type 2 diabetes have their treatment deintensified, suggests an analysis of Veterans Affairs data.
Older adults with type 1 diabetes spend more time in target glucose range when using the Cambridge hybrid closed-loop insulin delivery system than when using sensor-augmented pump delivery, shows a randomized trial.
Older adults with a longer duration of type 1 diabetes have an increased likelihood of experiencing depression and hypoglycemia unawareness, researchers report.